Autoantibodies raise suspicion; IgG, histology, and exclusion of mimics make the case coherent.
Reference image for orientation, not a diagnostic studyAutoimmune hepatitis is established by a compatible clinical, serologic, IgG, and interface-hepatitis pattern after excluding mimics.National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health / NIDDK, NIH (Public domain). SourcePublic domain
Use ANA, ASMA, anti-LKM1, IgG, and interface hepatitis without turning historical antibody patterns into treatment subtypes.
Exclude viral, drug-induced, metabolic, and cholestatic mimics before immunosuppression.
Plan glucocorticoid and azathioprine induction, maintenance, withdrawal assessment, relapse care, and transplant referral.
Rounds dashboard
See the whole liver patient
The dashboard keeps injury pattern, function, complications, and next action visible together.
Quick check
A 29-year-old woman has fatigue, ALT 612 U/L, AST 540 U/L, high IgG, positive ANA and ASMA, negative viral studies, and biopsy showing interface hepatitis rich in plasma cells.
Which interpretation is most accurate?
Autoimmune hepatitis is a clinicopathologic diagnosis built from concordant evidence.
Remission must be complete and sustained
Partial improvement is not the same as controlling the inflammatory driver.
Complete biochemical response means normalization of AST, ALT, and IgG; current guidance assesses response across 6 to 12 months while acting sooner on deterioration or insufficient response.
Treatment withdrawal is generally considered only after at least 2 years of sustained biochemical remission, not merely 2 years of therapy.
Relapse is common after withdrawal and usually requires prompt reinstitution of the previously effective regimen followed by long-term maintenance.
Position each state from controlled to urgent.
Serologic patterns guide suspicion, not certainty
Antibody profiles remain diagnostically useful, but current guidance does not recommend subclassifying adults for treatment by autoantibody pattern.
The historical type 1 pattern commonly includes ANA and/or ASMA, while LKM1 and LC1 reactivity is more frequent in younger children.
These patterns support diagnostic reasoning but do not define different adult treatment pathways; disease severity and response matter more.
High IgG supports the diagnosis and can track biochemical response, but some acute presentations have normal IgG.
Compare the diagnostic contribution of each marker.
Common in the historical type 1 pattern but nonspecific; it can occur in other liver diseases and healthy people.
Supports AIH in the right context but cannot establish the diagnosis alone.
Supports LKM1-related AIH, especially in a child, and requires distinction from antibodies seen with hepatitis C.
Polyclonal elevation strengthens the pattern and is followed with aminotransferases during treatment.
The more concordant the serology, IgG, histology, and exclusion data, the stronger the diagnosis.
Diagnose first, then induce and maintain remission
The sequence prevents immunosuppression from obscuring an untreated infection or a removable drug cause.
Characterize hepatocellular injury and hepatic function, then test conventional autoantibodies and serum IgG.
Exclude viral hepatitis, Wilson disease when age-appropriate, drug or supplement injury, alcohol-associated disease, MASLD, and cholestatic overlap when suggested.
Obtain liver biopsy to support diagnosis and stage injury unless a critical acute setting makes biopsy unsafe or treatment cannot wait.
Biopsy evaluates interface activity, plasma cells, rosettes, necrosis, and fibrosis while recognizing none is individually pathognomonic.
Start predniso(lo)ne and add azathioprine when appropriate; mycophenolate mofetil is a current first-line alternative but is teratogenic.
Taper glucocorticoid by response while continuing the steroid-sparing agent; follow AST, ALT, IgG, blood counts, and toxicity.
Interface hepatitis is the border-zone clue
The immune attack crosses the limiting plate, but the same pattern can appear in important mimics.
Interface hepatitis consists of portal inflammatory cells extending into periportal parenchyma across the limiting plate.
Plasma cell enrichment, hepatocyte rosettes, and emperipolesis can support autoimmune hepatitis but are neither universally present nor specific.
Biliary injury out of proportion to hepatitic injury should raise concern for primary biliary cholangitis, primary sclerosing cholangitis, or an overlap phenotype.
Choose the histologic statement that is safe to carry into practice.
Portal tracts contain the lymphoplasmacytic infiltrate; interface activity crosses into periportal hepatocytes.
Lobular hepatitis, confluent necrosis, or bridging necrosis can occur in more active or acute severe disease.
Repeated inflammation activates fibrogenesis, progressing from portal expansion to bridging fibrosis and cirrhosis.
Locate the finding and its consequence.
Lymphocytes and plasma cells accumulate around portal structures.
Interface activity breaches the portal-parenchymal boundary.
Lobular inflammation and necrosis can accompany active disease.
Persistent untreated injury can create fibrosis, cirrhosis, and portal hypertension.
Immunosuppression has phases and prerequisites
Induction suppresses active injury; maintenance preserves complete biochemical response with the least toxic effective regimen.
Prednisone or prednisolone induces remission; azathioprine is commonly introduced as a steroid-sparing maintenance partner after evaluating cytopenias, thiopurine risk, pregnancy context, and acute liver failure.
Mycophenolate mofetil is a current first-line alternative to azathioprine for induction and maintenance with predniso(lo)ne, but its teratogenicity requires explicit reproductive counseling.
Budesonide is not recommended as first-line treatment and is contraindicated in cirrhosis; at most, selected noncirrhotic predniso(lo)ne-dependent patients with steroid toxicity may be considered for a switch.
Reveal the role and boundary of each treatment decision.
Rapidly suppresses active immune injury; taper is guided by biochemical response and adverse effects.
Do not taper based on symptoms alone.
Either can be paired with predniso(lo)ne in current first-line care; azathioprine needs marrow and hepatic monitoring, while mycophenolate is teratogenic.
Do not use either as rescue monotherapy for acute liver failure.
Most patients need long-term therapy; consider withdrawal only after low-dose monotherapy has sustained complete biochemical response for at least 2 years.
Taper stepwise and monitor closely for relapse.
Indicated for acute liver failure, nonresponse with worsening dysfunction, or decompensated end-stage disease.
Do not delay referral while ineffective therapy continues.
Stage 1 of 3: Overview
Overview
Autoimmune Hepatitis
The sequence prevents immunosuppression from obscuring an untreated infection or a removable drug cause.
Step by step
Diagnose first, then induce and maintain remission
1Assemble and excludeCombine biochemistry, IgG, serology, medication history, viral testing, and competing diagnoses.
2Confirm and stageBiopsy evaluates interface activity, plasma cells, rosettes, necrosis, and fibrosis while recognizing none is individually pathognomonic.
3Induce remissionStart predniso(lo)ne and add azathioprine when appropriate; mycophenolate mofetil is a current first-line alternative but is teratogenic.
4Maintain and monitorTaper glucocorticoid by response while continuing the steroid-sparing agent; follow AST, ALT, IgG, blood counts, and toxicity.
Clinical takeaway
Why it mattersObtain liver biopsy to support diagnosis and stage injury unless a critical acute setting makes biopsy unsafe or treatment cannot wait.
RememberAutoimmune hepatitis is a clinicopathologic diagnosis built from concordant evidence.
Rounds question
Name today’s management pivot
Choose the clue that changes what the team does on this round.
Which interpretation is most accurate?
Key finding. A 29-year-old woman has fatigue, ALT 612 U/L, AST 540 U/L, high IgG, positive ANA and ASMA, negative viral studies, and biopsy showing interface hepatitis rich in plasma cells.
Answer. The combined pattern strongly supports autoimmune hepatitis after exclusion of mimics.
Why. Serology, IgG, histology, and exclusion work together.
Board rule. Autoimmune hepatitis is a clinicopathologic diagnosis built from concordant evidence.
Run the liver cases
A hepatology clinic evaluates five patients in whom antibodies, biopsy, medications, treatment response, and liver reserve point in different directions.
Cross out premature plans and highlight the finding that changes management. Each case separates injury, function, and complication.
A 34-year-old woman has ALT 480 U/L, high IgG, ANA 1:320, and interface hepatitis. She started minocycline 8 months ago for acne, and viral testing is negative.
What is the best next diagnostic action?
Reason it through
Which AIH features are present?High IgG, ANA positivity, and interface hepatitis form a supportive pattern.
What competing exposure can reproduce it?Minocycline can cause drug-induced autoimmune-like hepatitis.
What observation helps separate the courses?Improvement and lack of relapse after drug withdrawal favor a drug-induced process.
A convincing autoimmune pattern still requires a medication timeline.
Which AIH features are present?What competing exposure can reproduce it?
Which AIH features are present?High IgG, ANA positivity, and interface hepatitis form a supportive pattern.
What competing exposure can reproduce it?Minocycline can cause drug-induced autoimmune-like hepatitis.
What observation helps separate the courses?Improvement and lack of relapse after drug withdrawal favor a drug-induced process.
A 12-year-old girl presents with jaundice, marked aminotransferase elevation, high IgG, and positive anti-LKM1. Hepatitis C testing is negative.
Which interpretation is most appropriate under current nomenclature?
Reason it through
What diagnostic pattern does anti-LKM1 support?It supports LKM1-related autoimmune hepatitis, especially in a child.
What infectious mimic matters for interpretation?Hepatitis C can be associated with LKM reactivity and should be excluded.
What should the label not determine?Historical type labels should not determine a different treatment pathway.
Anti-LKM1 is a diagnostic clue, not a separate adult treatment algorithm.
What diagnostic pattern does anti-LKM1 support?What infectious mimic matters for interpretation?
What diagnostic pattern does anti-LKM1 support?It supports LKM1-related autoimmune hepatitis, especially in a child.
What infectious mimic matters for interpretation?Hepatitis C can be associated with LKM reactivity and should be excluded.
What should the label not determine?Historical type labels should not determine a different treatment pathway.
A 45-year-old woman with newly diagnosed AIH has no cirrhosis. Prednisone controls her inflammation, and azathioprine is being considered to reduce steroid exposure.
Which monitoring plan is most appropriate?
Reason it through
Why add azathioprine?It supports maintenance and reduces cumulative glucocorticoid exposure.
Which toxicity is easy to miss without testing?Bone marrow suppression can present as cytopenias.
What defines treatment success?Normalization of AST, ALT, and IgG.
Steroid sparing requires toxicity monitoring and a complete biochemical target.
Why add azathioprine?Which toxicity is easy to miss without testing?
Why add azathioprine?It supports maintenance and reduces cumulative glucocorticoid exposure.
Which toxicity is easy to miss without testing?Bone marrow suppression can present as cytopenias.
What defines treatment success?Normalization of AST, ALT, and IgG.
A 39-year-old man with AIH has normal AST, ALT, and IgG for 8 months on azathioprine after a prednisone taper. He asks to stop all medication.
What is the most appropriate next step?
Reason it through
What has he achieved?He has complete biochemical remission.
What has he not achieved?He has not sustained that remission for the usual minimum withdrawal consideration period.
Why be cautious?Relapse after withdrawal is common and recurrent inflammation can scar the liver.
Remission is a state to sustain, not a brief laboratory event.
What has he achieved?What has he not achieved?
What has he achieved?He has complete biochemical remission.
What has he not achieved?He has not sustained that remission for the usual minimum withdrawal consideration period.
Why be cautious?Relapse after withdrawal is common and recurrent inflammation can scar the liver.
A 26-year-old woman presents with acute severe AIH, rising INR, and new hepatic encephalopathy despite initial glucocorticoid treatment. Imaging shows no chronic portal hypertension.
What is the most appropriate next step?
Reason it through
What syndrome is now present?Coagulopathy plus encephalopathy indicates acute liver failure.
Why is routine outpatient induction inadequate?Her liver reserve is deteriorating despite initial therapy.
What action is time critical?Urgent transplant-center evaluation.
When INR rises and encephalopathy appears, transplant evaluation runs in parallel with treatment.
What syndrome is now present?Why is routine outpatient induction inadequate?
What syndrome is now present?Coagulopathy plus encephalopathy indicates acute liver failure.
Why is routine outpatient induction inadequate?Her liver reserve is deteriorating despite initial therapy.
What action is time critical?Urgent transplant-center evaluation.
Rapid review
Three questions to check
Which interpretation is most accurate?
The combined pattern strongly supports autoimmune hepatitis after exclusion of mimics.. Serology, IgG, histology, and exclusion work together.
Which AIH features are present?
High IgG, ANA positivity, and interface hepatitis form a supportive pattern.
What competing exposure can reproduce it?
Minocycline can cause drug-induced autoimmune-like hepatitis.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
